With multi-indication PBS listing widening immunotherapy access for advanced and metastatic cancers, ‘clinical judgement and discretion’ takes on new meaning for oncologists. Watch again as an expert panel shares evidence-based, practical insights for assessing and managing patients with immunotherapy-resistant cancers.

Click on chapters below to view topics

Chapter 1: Perspectives from patient advocacy organisation

Chapter 2: Communication and aspects of managing challenging consultations

Chapter 3: Common sense oncology consideration of pan-cancer IO access

Chapter 4: Mechanisms of IO resistance and negative evidence thresholds

Developed in partnership with MOGA

Hosted by Associate Professor James Lynam
Chair, Medical Oncology Group of Australia (MOGA); Senior Clinical Advisor, Cancer Institute NSW.

PANEL

Professor Clare Scott. Professor of Gynaecological Cancer, University of Melbourne; Joint Head, Clinical Translation Centre and Laboratory Head, Walter and Eliza Hall Institute of Medical Research; Medical Oncologist, Peter MacCallum Cancer Centre, Royal Melbourne and Royal Women’s Hospitals.

Christine Cockburn. Chief Executive Officer, Rare Cancers Australia.

Dr Samuel Stevens. Common Sense Oncology Fellow in Cancer Policy, Queen’s University; VMO – Medical Oncologist, NSW Health.

Dr Anupriya Agarwal. Medical Oncologist, Mater Hospital; Clinical Senior Lecturer, University of Sydney.

For more information, please contact [email protected]

Thank you to our partner

Sponsored  by

These webinars were supported by unrestricted educational grants and created independently by the Medical Oncology Group of Australia (MOGA) in collaboration with the limbic. All content is selected by the participants and all views expressed are those of the participants only.